Answers are grounded in this paper and cite their sources.
. Animals treated orally with LASSBio-1736n (12.5 mg/kg/day for 10 days) showed a significant reduction (85.48%) in splenic parasite burden compared to Glucantime. This effect was associated with cytokine modulation (increased IL-10 and reduced IFN-γ) and histopathological improvement, including reduced granuloma area, balanced parenchyma/interstitium ratio, and normalized hepatocyte glycogen distribution. LASSBio-1736f showed milder effects, whereas Glucantime induced a stronger pro-inflammatory response. Overall, these findings demonstrate that albumin-based nanocarriers enhance the in vivo efficacy of LASSBio-1736 and support its development as a promising orally deliverable therapy for VL.
No takes yet. Share an insight, caveat, or question.
Nunes et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: